Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control

Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Trial and Add Two U.S. Sites; Early Interim Results Showed 100% Local Disease Control

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.